Eirini Papapetrou, MD, PhD, is an Associate Professor of Oncological Sciences, Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai. Dr Papapetrou’s research program seeks to uncover new disease mechanisms and therapeutic targets for myeloid neoplasms. Dr Papapetrou pioneered the development of induced pluripotent stem cell (iPSC) models of myeloid malignancies. Her laboratory leverages genetically faithful isogenic iPSC models of myeloid malignancies generated through patient cell reprogramming and precise CRISPR-mediated gene editing and exploits the unique capabilities they offer towards target discovery and validation through mechanistic interrogation, genetic and chemical screens, and functional studies. Dr. Papapetrou is the recipient of several prestigious awards, including the American Society of Gene and Cell Therapy Outstanding New investigator Award, Damon Runyon-Rachleff Innovation Award, Pershing Square Sohn Prize and is an elected member of the American Society for Clinical Investigation.